Results 71 to 80 of about 65,459 (255)
Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. [PDF]
, 1985 Autoimmune NZB/NZW mice were treated with weekly injections of monoclonal antibody (mAb) to L3T4, an antigen expressed on a distinct subpopulation of T cells that respond to class II major histocompatibility antigens.
Seaman, WE, Wofsy, D
core +1 more source
Advanced Science, EarlyView.Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Lupus nephritis in males; updates to current knowledge [PDF]
Journal of Nephropharmacology, 2019 Studies have demonstrated that male systemic lupus erythematosus (SLE) patients present with atypical manifestations, serious kidney involvement and worse prognosis.
Faizan Shaukat +3 more
doaj +1 more source
IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis [PDF]
, 2019 An acquired deficiency of interleukin-2 (IL-2) and related disturbances in regulatory T cell (Treg) homeostasis play an important role in the pathogenesis of systemic lupus erythematosus (SLE).
Burmester, Gerd-Rüdiger +8 more
core +2 more sources
Animal Models and Experimental Medicine, EarlyView.Pristane (5 mL/kg) induced a robust systemic lupus erythematosus (SLE)‐like phenotype in Macaca fascicularis, marked by elevated antinuclear antibody (ANA) levels and systemic clinical, hematological, and biochemical changes. This model closely reflects human SLE and provides a translational platform for disease studies and therapeutic evaluation ...
Jonny Jonny +12 more
wiley +1 more source
Case Reports in Nephrology, 2019 Lupus nephritis is a common manifestation of systemic lupus erythematosus (SLE). IgA nephropathy is a common type of primary glomerulonephritis. Renal manifestations in SLE patients are often due to lupus nephritis; however, renal diseases unrelated to ...
Amol M. Patel +5 more
doaj +1 more source
Questions about Chemokine and Chemokine Receptor Antagonism in Renal Inflammation [PDF]
, 2010 Chemokines remain attractive therapeutic targets for modulating inflammatory diseases in all areas of medicine including acute and chronic kidney disease.
Anders, Hans-Joachim +2 more
core +1 more source
Arthritis &Rheumatology, EarlyView.Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley +1 more source
Increased Urinary Exosomal MicroRNAs in Patients with Systemic Lupus Erythematosus. [PDF]
PLoS ONE, 2015 There is increased interest in using microRNAs (miRNAs) as biomarkers in different diseases. Present in body fluids, it is controversial whether or not they are mainly enclosed in exosomes, thus we studied if urinary miRNAs are concentrated inside ...
Javier Perez-Hernandez +5 more
doaj +1 more source
Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort [PDF]
, 2015 Objectives. The anti-dsDNA antibodies are a marker for Systemic Lupus Erythematosus (SLE) and 70–98% of patients test positive. We evaluated the demographic, clinical, laboratory, and therapeutical features of a monocentric SLE cohort according to the ...
Alessandri, Cristiano +9 more
core +1 more source